Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Certolizumab pegol

🥰Excellent
Catalog No. T76963Cas No. 428863-50-7
Alias PHA-738144, PHA738144, Certolizumab, CDP870, CDP8 70

Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

Certolizumab pegol

Certolizumab pegol

🥰Excellent
Catalog No. T76963Alias PHA-738144, PHA738144, Certolizumab, CDP870, CDP8 70Cas No. 428863-50-7
Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
Pack SizePriceAvailabilityQuantity
1 mg$147In Stock
5 mg$313In Stock
10 mg$496In Stock
25 mg$793In Stock
50 mg$1,070In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:8.66 mg/mL
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
Targets&IC50
TNF-α:3 ng/mL (IC90)
In vitro
Certolizumab pegol was able to neutralize soluble TNFα with an IC90 value of 3 ng/mL.Certolizumab pegol was able to completely inhibit IL-1β production by human monocytes in response to LPS stimulation after treatment at concentrations ranging from 0-100 μg/mL for 1 h. Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). In addition, Certolizumab pegol does not induce apoptosis in activated human monocytes or peripheral blood lymphocytes (PBL), nor does it cause degranulation or disruption of cell membrane integrity in polymorphonuclear cells. [1]
In vivo
Acute edematous pancreatitis was induced in healthy Wistar Albino male rats by intraperitoneal injection of 80 μg/kg of Cerulein (20 μg/kg each time for 4 doses, 1 hour apart). Subsequently, a single intraperitoneal injection of 10 μg Certolizumab pegol significantly reduced serum levels of amylase, lipase and lactate dehydrogenase. Histopathologic examination showed significant reductions in edema, hemorrhage, parenchymal necrosis, and infiltration scores. In addition, malondialdehyde, myeloperoxidase, TNF-α and caspase-3 activities were significantly reduced. [2]
AliasPHA-738144, PHA738144, Certolizumab, CDP870, CDP8 70
Chemical Properties
Cas No.428863-50-7
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Certolizumab pegol | purchase Certolizumab pegol | Certolizumab pegol cost | order Certolizumab pegol | Certolizumab pegol in vivo | Certolizumab pegol in vitro